Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Innate Pharma S.A.

IPHYFPNK
Healthcare
Biotechnology
$1.99
$-0.16(-7.66%)
U.S. Market opens in 9h 43m

Innate Pharma S.A. Fundamental Analysis

Innate Pharma S.A. (IPHYF) shows weak financial fundamentals with a PE ratio of -3.12, profit margin of -8.97%, and ROE of -6.59%. The company generates $0.0B in annual revenue with weak year-over-year growth of -75.68%.

Key Strengths

Cash Position35.33%
PEG Ratio-0.38
Current Ratio2.21

Areas of Concern

ROE-6.59%
Operating Margin-9.87%
We analyze IPHYF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1397.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1397.8/100

We analyze IPHYF's fundamental strength across five key dimensions:

Efficiency Score

Weak

IPHYF struggles to generate sufficient returns from assets.

ROA > 10%
-49.55%

Valuation Score

Excellent

IPHYF trades at attractive valuation levels.

PE < 25
-3.12
PEG Ratio < 2
-0.38

Growth Score

Weak

IPHYF faces weak or negative growth trends.

Revenue Growth > 5%
-75.68%
EPS Growth > 10%
-5.48%

Financial Health Score

Moderate

IPHYF shows balanced financial health with some risks.

Debt/Equity < 1
5.25
Current Ratio > 1
2.21

Profitability Score

Weak

IPHYF struggles to sustain strong margins.

ROE > 15%
-658.91%
Net Margin ≥ 15%
-8.97%
Positive Free Cash Flow
No

Key Financial Metrics

Is IPHYF Expensive or Cheap?

P/E Ratio

IPHYF trades at -3.12 times earnings. This suggests potential undervaluation.

-3.12

PEG Ratio

When adjusting for growth, IPHYF's PEG of -0.38 indicates potential undervaluation.

-0.38

Price to Book

The market values Innate Pharma S.A. at 27.97 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

27.97

EV/EBITDA

Enterprise value stands at -3.98 times EBITDA. This is generally considered low.

-3.98

How Well Does IPHYF Make Money?

Net Profit Margin

For every $100 in sales, Innate Pharma S.A. keeps $-8.97 as profit after all expenses.

-8.97%

Operating Margin

Core operations generate -9.87 in profit for every $100 in revenue, before interest and taxes.

-9.87%

ROE

Management delivers $-6.59 in profit for every $100 of shareholder equity.

-6.59%

ROA

Innate Pharma S.A. generates $-49.55 in profit for every $100 in assets, demonstrating efficient asset deployment.

-49.55%

Following the Money - Real Cash Generation

Operating Cash Flow

Innate Pharma S.A. generates limited operating cash flow of $-45.11M, signaling weaker underlying cash strength.

$-45.11M

Free Cash Flow

Innate Pharma S.A. generates weak or negative free cash flow of $-45.30M, restricting financial flexibility.

$-45.30M

FCF Per Share

Each share generates $-0.48 in free cash annually.

$-0.48

FCF Yield

IPHYF converts -26.13% of its market value into free cash.

-26.13%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-3.12

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.38

vs 25 benchmark

P/B Ratio

Price to book value ratio

27.97

vs 25 benchmark

P/S Ratio

Price to sales ratio

30.75

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

5.25

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.21

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-6.59

vs 25 benchmark

ROA

Return on assets percentage

-0.50

vs 25 benchmark

ROCE

Return on capital employed

-0.80

vs 25 benchmark

How IPHYF Stacks Against Its Sector Peers

MetricIPHYF ValueSector AveragePerformance
P/E Ratio-3.1229.45 Better (Cheaper)
ROE-658.91%779.00% Weak
Net Margin-896.63%-24936.00% (disorted) Weak
Debt/Equity5.250.26 Weak (High Leverage)
Current Ratio2.214.65 Strong Liquidity
ROA-49.55%-19344.00% (disorted) Weak

IPHYF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Innate Pharma S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-79.90%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-161.71%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-121.68%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ